AUG 30, 2016 08:00 AM PDT

Human umbilical cord mesenchymal cells and the treatment of bronchopulmonary dysplasia

  • Chief Executive Officer, Meridigen Biotech Co., Ltd., Taiwan
      Dr. Willie Lin received his Bachelor of science in Animal Sciences from Tunghai University in Taiwan followed by a doctorate in Biochemistry from Kansas State University in the USA. He is currently serving as the Chief Executive Officer of Meridigen Biotech based in Taiwan. Dr. Lin's professional experience has included: Adjunct Associate Professor of the Master Program in Technology Management at Fu Jen Catholic University; Chairman and President of Microbio Co., Ltd and Fountain Biopharma, Inc; President and Chief Operating Officer at UniMed Venture Management, Inc; Associate Vice President of the Strategy and Planning Department at China Chemical and Pharmaceutical Co.; and Associate Vice President in the Overseas Business Department for the China Development Industrial Bank.

    The human umbilical cord is a promising abundant source of mesenchymal stem cells (MSCs). Compare to other MSCs, the advantages of human umbilical cord MSCs (hUC-MSCs) are easily accessible and they have a short amplification time, high proliferation rate, lower immunogenicity, and abundance. Many studies have shown that hUC-MSCs have the ability to differentiate into three germ layers, to accumulate in damaged tissue or inflamed regions, to promote tissue repair, and to modulate immune response. Thus, they are attractive human cell–based therapies for the treatment of bronchopulmonary dysplasia, chronic obstructive pulmonary disease, ischemic stroke, neuron degenerative diseases, autoimmune diseases, etc.

    Show Resources
    Loading Comments...